Schonfeld Strategic Advisors LLC Oncternal Therapeutics, Inc. Transaction History

Schonfeld Strategic Advisors LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 14, 2023	SELL	$0.86 - $22.2 $6,450 - $166,500	-7,500 Reduced 36.95%	12,800 $12,000
Q2 2022 Aug 15, 2022	SELL	$0.7 - $1.56 $140 - $312	-200 Reduced 0.98%	20,300 $23,000
Q1 2022 May 16, 2022	BUY	$1.37 - $2.43 $28,085 - $49,815	20,500 New	20,500 $28,000
Q3 2021 Nov 16, 2021	SELL	$3.37 - $4.76 $54,765 - $77,354	-16,251 Closed	0 $0
Q2 2021 Aug 16, 2021	SELL	$4.75 - $9.39 $403,507 - $797,671	-84,949 Reduced 83.94%	16,251 $77,000
Q1 2021 May 17, 2021	BUY	$4.59 - $9.04 $139,536 - $274,816	30,400 Added 42.94%	101,200 $842,000
Q4 2020 Feb 16, 2021	BUY	$1.51 - $6.3 $106,908 - $446,040	70,800 New	70,800 $347,000

362K

Ticker ONCT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,517,200
Market Cap $29.4M
Description
Oncternal Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of oncology therapies for cancers with critical unmet medical needs. The company's clinical pipeline includes zilovertamab, a humanized monoclonal antibody that binds to receptor-tyrosine kinase-like Orphan Receptor 1 (ROR1); and ONCT-216, a smal...

Get notified when there are updates to the investment portfolio of Schonfeld Strategic Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Schonfeld Strategic Advisors LLC with notifications on news.